A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.

摘要: Purpose Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with anlotinib versus alone for metastatic/advanced non-small cell lung cancer (NSCLC) in patients who failed first- or second-line systemic treatment China. Patients methods In this retrospective trial, ninety-four advanced NSCLC received (n = 41) 53) Henan Cancer Hospital. recorded objective response rate (ORR), disease control (DCR), progression-free survival (PFS) adverse events (AEs). Results plus group, eleven (27%) achieved PR (partial response), twenty-one (51%) SD (stable disease), an ORR 27% DCR 78%. eight (15%) PR, nineteen (36%) had SD, 15% 51%. The combination arm was slightly, but not obviously, higher than that (27% vs 15%, p > 0.05). addition, significantly (78% 51%, p=0.007). At end follow-up, 1.5-month longer median PFS arm; difference statistically significant (5.0 3.5, p=0.002). OS at final analysis. hematological nonhematological toxicities were well tolerated controlled. general, most limited to grade I II, Conclusion Our study suggests may be effective well-tolerated fail therapy.